Immedica welcomes Heidi Ramstad as new Chief Medical Officer

news

It is with great pleasure we can announce that Heidi Ramstad has been offered and accepted the position as Chief Medical Officer (CMO) at Immedica Pharma. Heidi is a Medical Doctor (MD) and Specialist in Pediatric Medicine. She has many years of academic and pharmaceutica industry experience. As an example, she has Medical Affairs experience […]

ZepzelcaTM (lurbinectedin) approved in United Arab Emirates (UAE) for the treatment of metastatic Small Cell Lung Cancer (SCLC)

news

Immedica Pharma AB announces that the United Arab Emirates Ministry of Health and Prevention has approved ZepzelcaTM (lurbinectedin) – for the treatment of metastatic Small Cell Lung Cancer (SCLC).  “Small cell lung cancer is a disease with limited treatment options. The approval of Zepzelca in United Arab Emirates represents an important treatment option for patients […]

Immedica acquires the rights for additional Ophthalmology products for European countries

news

Immedica Pharma AB (Immedica) has acquired rights from Novartis to five ophthalmology products involving indications for the treatment of glaucoma and inflammatory conditions of the eye, in certain European countries. The deal encompasses commercial and distribution rights and intellectual property for the five products in the territories. All five products are part of standard pharmaceutical […]

Immedica and WinHealth enter agreement giving Winhealth rights to Ravicti® in China and several other Asia-Pacific countries

news

Stockholm, Hangzhou, December 30, 2020 – Immedica Pharma AB and Hongkong WinHealth Pharma Group CO., Ltd, today announce that they have entered an agreement under which WinHealth gains the exclusive commercial rights to Ravicti® (glycerol phenylbutyrate), in a territory covering the Greater China Area , South Korea, Singapore, Vietnam, Indonesia, Malaysia, Philippines and Thailand. The […]

Immedica acquires the rights for Ravicti® and Buphenyl® for Japan from Horizon Therapeutics plc.

news

Stockholm, November 6th, 2020 – Immedica today announces that it has acquired the rights for the products Buphenyl® (sodium phenylbutyrate) and Ravicti® (glycerol phenylbutyrate) indicated for the treatment of Urea Cycle Disorders (UCD), in Japan from Horizon Therapeutics plc (Nasdaq: HZNP) (Horizon). As part of the transaction, Horizon’s existing distribution agreement with Japanese rare disease […]

PharmaMar signs an agreement with Immedica

news

PharmaMar signs an agreement with Immedica Pharma to market lurbinectedin in Eastern Europe, the UK, Ireland, the Nordic countries and some Middle Eastern countries Madrid, April 29th, 2020 – PharmaMar (MSE:PHM) has announced today that it has signed an agreement with Immedica Pharma AB (Immedica) for the exclusive distribution and marketing, if approved, of the […]

Immedica speaker at the Nordic American Life Science Conference 2019 in New York City

news

Commercialization of niche specialty care pharmaceutical products in Europe is a truly complex and multifaceted process. As a demonstration of its expertise in this area, Immedica was in December invited to present at the 2019 Nordic American Life Science Conference in New York City gathering more than 200 participants representing mainly US investors as well […]

Immedica acquires the rights for Ophthalmology products for European countries

news

Immedica Pharma AB (Immedica) has acquired rights to four ophthalmology products involving indications for the treatment of glaucoma, allergic conjunctivitis, and inflammatory conditions of the eye, in certain European countries from Novartis. The deal encompasses commercial and distribution rights and intellectual property for the four products in the territories. All four products are since long […]